A Single Dose of Pegylated Leridistim Significantly Improves Neutrophil Recovery in Sublethally Irradiated Rhesus Macaques
- 1 November 2001
- journal article
- Published by Oxford University Press (OUP) in The International Journal of Cell Cloning
- Vol. 19 (6), 514-521
- https://doi.org/10.1634/stemcells.19-6-514
Abstract
Leridistim, a member of the myelopoietin family of dual receptor agonists that binds interleukin-3 and G-CSF receptors, has been shown to enhance hematopoietic activity in rhesus monkeys above that observed with either cytokine alone or in combination. This study demonstrated the ability of a pegylated form of leridistim (peg-leridistim), administered s.c., as a single- or two-dose regimen separated by 4 or 7 days, to significantly improve neutrophil recovery following radiation-induced myelosuppression. Rhesus macaques were total body x-irradiated (250 kVp, TBI) to 600 cGy. Following TBI, two groups received peg-leridistim (n = 5) or leridistim (n = 4) at a dose of 600 microg/kg on day 1, while two other groups (both n = 4) received peg-leridistim at 200 microg/kg on day 1 and day 4, or day 1 and day 7. The irradiation controls (n = 7) received 0.1% autologous serum for 18 days. All peg-leridistim treatment schedules significantly improved all neutrophil-related parameters following TBI as compared with nontreated controls and were equivalent in effect when compared among themselves. Administration of a single high dose or two separate lower doses of peg-leridistim significantly improved neutrophil regeneration, in a manner equal to that of conventional daily or abbreviated every-other-day administration of leridistim in this nonhuman primate model of severe myelosuppression.Keywords
This publication has 4 references indexed in Scilit:
- Leridistim, a Chimeric Dual G‐CSF and IL‐3 Receptor Agonist, Enhances Multilineage Hematopoietic Recovery in a Nonhuman Primate Model of Radiation‐Induced Myelosuppression: Effect of Schedule, Dose, and Route of AdministrationThe International Journal of Cell Cloning, 2001
- Myelopoietin, an engineered chimeric IL-3 and G-CSF receptor agonist, stimulates multilineage hematopoietic recovery in a nonhuman primate model of radiation-induced myelosuppressionBlood, 2000
- A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humansExperimental Hematology, 1999
- Combined administration of recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor enhances multilineage hematopoietic reconstitution in nonhuman primates after radiation-induced marrow aplasia.JCI Insight, 1996